@duchessofdecorum's peptide therapy claims, fact-checked

What did @duchessofdecorum actually say?

The creator describes a years-long illness involving mono, concurrent COVID-19 infection, and eventual long COVID diagnosis. She reports spending over $70,000 on treatments including acupuncture, immunoglobulin therapy (IVIG/SCIG), and low-dose naltrexone (LDN), before being introduced to peptide therapy by a hormone specialist. She frames long COVID as "inflammation of your entire body and especially of your central nervous system" and describes LDN as moving her from "20% to 30%" of normal function. She did not finish her account of what the peptides actually did, but the hashtags and caption strongly imply they were the thing that "finally worked."

To her credit, she includes a medical disclaimer and does not claim to be a professional. The framing is personal journey, not medical advice. That said, 21,700 viewers are drawing conclusions from this regardless of the disclaimer language.

Does the science back this up?

On the core claim that long COVID involves systemic inflammation and central nervous system disruption, she is broadly correct. The evidence here is real, though the full picture is more complicated than a single-cause story.

Long COVID is not one disease. Research published by Davis et al. (2023, Nature Reviews Microbiology) identified over 200 symptoms across multiple organ systems and proposed at least four overlapping mechanisms: viral persistence, immune dysregulation, microbiome disruption, and reactivation of latent viruses like Epstein-Barr, which causes mono. That last point is relevant here, because her mono infection preceding COVID is not just coincidence. EBV reactivation has been documented in a meaningful subset of long COVID patients, and her sequential infection story actually fits the published literature better than she probably realizes.

On LDN: the anti-inflammatory mechanism she describes is real, though simplified. LDN at doses between 1.5 and 4.5 mg appears to modulate microglial activity and reduce pro-inflammatory cytokine signaling. A 2024 pilot trial by Younger et al. showed symptom reduction in fibromyalgia, and LDN is increasingly used off-label in long COVID clinics. The 30% improvement she reported is subjective, but the direction is plausible.

What did they get wrong (or right)?

She gets long COVID's inflammatory character mostly right, but the framing that it is primarily "inflammation of your entire body" flattens a genuinely heterogeneous condition. Some patients present with dysautonomia as the primary driver. Others show evidence of microclots (Pretorius et al., 2022, Cardiovascular Diabetology). Calling it simply body-wide inflammation could lead viewers to seek anti-inflammatory treatments when their actual mechanism is different, and that matters for treatment matching.

Her description of SCIG (subcutaneous immunoglobulin therapy) is accurate in mechanics. Three-needle subcutaneous infusion is the standard SCIG delivery method. Her description of the stomach swelling temporarily after infusion is also accurate and a known, benign side effect of subcutaneous fluid volume.

What she gets wrong, or at least oversimplified: the implication that immunoglobulin therapy failed her because her problem "wasn't her immune system." IVIG and SCIG trials in long COVID are mixed and ongoing. Her immune dysfunction and her fatigue could share a single root cause that neither treatment fully addressed. Dismissing immunoglobulin therapy as a dead end because fatigue persisted may not be the right read of her own case.

The peptide claims are incomplete because she did not finish describing them. That absence is worth noting. We are fact-checking a setup, not a conclusion.

What should you actually know?

Long COVID currently has no FDA-approved treatment. That is not defeatism, it is a regulatory fact. LDN is used off-label with some supportive evidence but no large randomized controlled trial specifically in long COVID as of this writing. Peptides like BPC-157, TB-500, and others referenced in the video's category tags have extremely limited human trial data. Most research is animal-model or in vitro. Using them for long COVID specifically is experimental, full stop.

The $70,000 figure she cites is not implausible given the documented financial burden of long COVID. A 2023 analysis in the American Journal of Managed Care estimated average annual out-of-pocket costs for long COVID patients at several thousand dollars, with complex cases running far higher, particularly when treatments are not covered by insurance. Acupuncture, functional medicine, and peptide therapy are rarely covered.

If you have long COVID symptoms, a rheumatologist or a dedicated long COVID clinic is a reasonable starting point. The NIH RECOVER initiative is actively recruiting participants and offers access to emerging trials without the out-of-pocket cost of experimental peptide protocols.

The bottom line on the peptide framing

The video cuts off before the creator explains what the peptides actually did. The hashtag "peptidetherapy" and the caption's implication that something "finally worked" points toward a peptide endorsement that viewers are meant to infer. That is a meaningful gap between what was said and what is being communicated. Viewers should be cautious about drawing treatment conclusions from a narrative that ends mid-sentence. Peptide therapy for long COVID is not established medicine. That does not make it wrong for every patient, but it is not a proven path, and it should not be pursued without medical supervision from someone who understands your specific case and its documented mechanisms.